Paclitaxel-eluting stent is used to prevent cell proliferation and avoid fibrosis that could block the stented artery with the clots in a process called restenosis. The stents are scaffolds that can be placed inside diseased or narrowed coronary arteries to release a drug (at a slow speed) to inhibit cell proliferation.

The global Paclitaxel-eluting Stent market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Paclitaxel-eluting Stent volume and value at global level, regional level and company level. From a global perspective, this report represents overall Paclitaxel-eluting Stent market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Paclitaxel-eluting Stent in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Paclitaxel-eluting Stent manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
B.Braun Melsengen AG
Biosensors
Biotronik
Blue Medical
Boston Scientific
DISA Vascular
Essen
Medtronic Vascular
MicroPort Medical
Terumo Medical
Orbusneich

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Metal Stent
Polymer Stent
Others

Segment by Application
Coronary Heart Disease
Clinical
Others